| Health / Medical Topics |
TPH Inhibitor LX1606
An orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor prodrug with potential antiserotonergic activity. Upon administration, TPH inhibitor LX1606 is converted to its active metabolite LP-778902, which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
A regimen consisting of docetaxel, cisplatin and fluorouracil used for the treatment of squamous cell head and neck cancer.
An abbreviation for a chemotherapy combination used to treat certain types of head and neck cancer and stomach cancer. It includes the…
Human TPD52L1 wild-type allele is located within 6q22-q23 and is approximately 111 kb in length. This allele, which encodes tumor protein D53,…
This gene is involved in the regulation of cell division.
Human TPD52 wild-type allele is located in the vicinity of 8q21 and is approximately 137 kb in length. This allele, which encodes…
This gene plays a role in morphogenesis. It is putatively involved in calcium-mediated signal transduction and regulation of cell proliferation.
